Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (137)
- Compliance and enforcement (35)
- Import and export (35)
- Shortages and supply disruptions (17)
- Sunscreens (10)
- Advertising (7)
- COVID-19 (5)
- Labelling and packaging (5)
- Weight loss products (5)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Cosmetics (1)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
1309 result(s) found, displaying 1126 to 1150
-
Safety alertsDuring the 2010 influenza season an excess number of cases of febrile reactions and febrile convulsions were observed in paediatric populations following immunisation with one of the registered seasonal trivalent influenza vaccines.
-
Safety alertsSATURO capsules pose a serious health risk and should not be taken. They contain undeclared sildenafil. This may be harmful if taken without medical supervision.
-
Safety alertsOn 26 January 2011, the US Food and Drug Administration (FDA) announced a safety communication to warn about an association between breast implants and anaplastic large cell lymphoma. The risk of a patient developing this type of lymphoma is very low.
-
Market actionsThere have been some instances in Europe where the controller on the subject units has spontaneously ignited due to a faulty controller setting.
-
Market actionsMinicrosser-Cyclone DX, 3- and 4-wheel mobility scooters, Models 130T & 140T, manufactured before January 2007, are being recalled.
-
Market actionsThe combination of products may not be suitable for use as a vehicle transport device.
-
Market actionsOtto Bock Australia Pty Ltd has initiated a recall of a number of mobility chairs consisting of the combination of the Otto Bock Discovery Wheelbase and the Leckey Mygo Seat.
-
Safety alertsAbbott Diabetes Care has identified a problem associated with the slow filling with certain lots of Optium blood glucose test strips.
-
Safety alertsSlimming Factor weight loss capsules pose a serious health risk and should not be taken. The contain undeclared sibutramine, fenfluramine and phenolphthalein. All substances have serious safety concerns.
-
-
Market actionsWe are recalling Thelin (sitaxentan) worldwide due to serious liver risks. Consult your doctor if you have concerns.
-
Safety alertsSeasonal flu vaccine: Response to the West Australian (Stokes) Review
-
Market actionsSome cartons of Perindopril 2mg tablets labelled with batch numbers 24967, 24979, 25180, 25184 may contain Perindopril 8mg tablets
-
-
Market actionsWe have notified Johnson & Johnson Pacific that we are undertaking a consumer level recall of selected lots of 1-Day Acuvue TruEye contact lenses, as a precautionary measure.
-
Market actionsSponsor dispatched recall letters to all affected optometrists
-
Safety alertsSo Hard for Men tablets, Shaguar tablets and Pulse8 for Women capsules pose a serious risk to your health and should not be taken. They contain undeclared tadalafil and have not been assessed for quality, safety or efficacy.
-
-
Market actionsWeight loss drug Sibutramine (Reductil) withdrawn in Australia due to heart risks.
-
Safety alertsThe national immunisation program with Panvax® began on 30 September 2009. The TGA has been closely monitoring any side effects from the use of the vaccine.
-
Market actionsThe Therapeutic Goods Administration (TGA) has received enquiries about the recall of the LCS® DuofixTM Femoral Knee Replacement Component.
-
Safety alertsThe TGA is aware that the French authorities have now released an updated statement in regard to the testing of the PIP implants:
-
Safety alertsWe are analysing the safety of the Panvax H1N1 vaccine following reports of febrile convulsions in children.
-
Safety alertsTGA safety alert on rosiglitazone (Avandia/Avandamet) highlights cardiovascular risks, including increased likelihood of myocardial ischaemia, and reinforces restricted use and prescribing precautions.
-
Market actionsThe Therapeutic Goods Administration (TGA) advises that Octapharma Australia Pty Ltd has agreed to a precautionary voluntary recall of all batches of Octagam intravenous immunoglobulin solutions from the Australian market.